Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| State of the Pharmaceutical Industry - Job Cuts and Site Closures | 8 | 17 |
| Workforce Reduction | 8 | 2 |
| Workforce Reduction by Job Type | 10 | 1 |
| Site Closures | 11 | 3 |
| Drivers for Workforce Reduction | 14 | 1 |
| Mergers and Acquisitions | 14 | 1 |
| Approval Rates and R&D Expenditure | 14 | 2 |
| Investment in Innovative Science | 16 | 1 |
| Late Stage Failures | 16 | 3 |
| Complex Clinical Trials | 19 | 1 |
| The Fourth Hurdle: Market Access Drug Pricing and Negotiation | 19 | 1 |
| Growth of Generic Medicines | 20 | 3 |
| Personalized Medicine and Diagnostics | 23 | 1 |
| Future Outlook | 23 | 1 |
| R&D Budgets | 23 | 2 |
| Managing Staff During the Redundancy Process | 25 | 7 |
| Managing the Transition | 25 | 1 |
| Communicating with Employees Across the Organization | 25 | 1 |
| Employee Consultations and Redundancy Conditions | 26 | 1 |
| EU Countries | 26 | 2 |
| US | 28 | 1 |
| Supporting Employees during the Transition | 28 | 1 |
| Networking | 28 | 1 |
| Careers Fairs and Outplacement Services | 29 | 1 |
| Productivity Following Restructuring | 29 | 1 |
| Costs Associated with Restructuring Companies | 29 | 1 |
| Morale | 30 | 1 |
| Conclusions | 31 | 1 |
| Managing Site Closures | 32 | 5 |
| Site Redesign: Selling and Repurposing Sites | 34 | 1 |
| Selling to CROs: GlaxoSmithKline s Zagreb and Verona Sites | 35 | 1 |
| Case Study: Pfizer s Ann Arbor Site | 35 | 1 |
| Case Study: AstraZeneca s Lund and Charnwood Sites | 35 | 1 |
| Case Study: Pfizer s Sandwich Site | 36 | 1 |
| Conclusion | 36 | 1 |
| Planning for the Future | 37 | 14 |
| Emerging Markets | 37 | 2 |
| Outsourcing | 39 | 1 |
| Outsourcing by Big Pharma | 39 | 1 |
| Clinical Research | 39 | 1 |
| Drug Discovery and Pre-clinical Research | 40 | 1 |
| Small and Specialist CROs | 41 | 2 |
| Spin-outs and Licensing | 43 | 2 |
| Hubs, Clusters and Life Science Incubators | 45 | 1 |
| Life Science Incubators | 45 | 2 |
| Big Pharma Bioscience Incubators | 47 | 1 |
| Pharma s Growth Close to Hubs and Clusters | 48 | 1 |
| Working with Academia | 48 | 1 |
| Employment Opportunities | 49 | 1 |
| Conclusion | 49 | 2 |
| Appendix | 51 | 4 |
| Abbreviations | 51 | 1 |
| References | 51 | 2 |
| Methodology | 53 | 1 |
| Primary Research | 53 | 1 |
| Secondary Research | 53 | 1 |
| Contacts Us | 53 | 1 |
| Disclaimer | 54 | 1 |